DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Damora Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$19.27+0.83 (+4.50%)
Close on Oct 19, 2026
- Market cap
- $1.18B
- P/E (TTM)
- 4.8
- Dividend yield
- 0.00%